Corbus Pharmaceuticals Announces Phase 1a Study Results of CRB-913
I'm PortAI, I can summarize articles.
Corbus Pharmaceuticals announced the completion of its Phase 1a study of CRB-913, demonstrating promising safety and weight loss results. The study showed a 2.9% placebo-adjusted weight loss by Day 14, with no serious adverse events reported. A Phase 1b study, "CANYON-1," has been initiated, with completion expected in summer 2026. Participants noted reduced food-related thoughts and cravings.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments